• Je něco špatně v tomto záznamu ?

Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers

CB. Albiñana, M. Pallocca, H. Fenton, W. Sopwith, CV. Eden, O. Akre, A. Auranen, F. Bocquet, M. Borges, E. Calvo, J. Corkett, SD. Cosimo, N. Gentili, J. Guérin, S. Jor, T. Kazda, A. Kolar, T. Kuschel, MJ. Lostes, C. Paratore, P. Pedrazzoli, M....

. 2024 ; 15 (4) : 743-750. [pub] 20240911

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019416

BACKGROUND: Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking. OBJECTIVES: The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development. METHODS: PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records. RESULTS: During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature. CONCLUSION: PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.

Biobank Innsbruck Innsbruck Austria

Charité Universitätsmedizin Berlin Berlin Germany

Cliniques Universitaires Saint Luc Brussels Belgium

Data Factory and Analytics Department Institut de Cancérologie de l'Ouest Nantes Angers France

Data Office Institut Curie Paris France

DIGICORE Bruxelles Belgium

Fondazione 1 R C C S Policlinico San Matteo Pavia PV Italy

Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Institute of Oncology Ljubljana Ljubljana Slovenia

Instituto Português de Oncologia do Porto Francisco Gentil Porto Portugal

IQVIA London United Kingdom

IRCCS Istituto Nazionale Tumori Regina Elena Rome Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola Italy

IRCCS San Raffaele Scientific Institute Milan Italy

Karolinska Comprehensive Cancer Center Stockholm Sweden

Leeds Teaching Hospitals NHS Trust Leeds United Kingdom

Maastricht Comprehensive Cancer Center Maastricht The Netherlands

Masaryk Memorial Cancer Institute Brno Jihomoravský Czechia

Oslo University Hospital Cancer Center Oslo Norway

Sestre Milosrdnice University Hospital Zagreb Croatia

START Madrid CIOCC Centro Integral Oncológico Clara Campal Madrid Spain

Tartu University Hospital Tartu Tartumaa Estonia

Tays Cancer Centre Pirkanmaa Finland

Trinity St James's Cancer Institute Dublin Ireland

University Cancer Center Frankfurt University Hospital Goethe University Frankfurt Germany

University Hospital San Luigi Gonzaga of Orbassano Orbassano TO Italy

Vall d'Hebron University Hospital Barcelona Spain

Vejle Hospital University of Southern Denmark Vejle Denmark

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019416
003      
CZ-PrNML
005      
20241024110745.0
007      
ta
008      
241015s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0044-1788331 $2 doi
035    __
$a (PubMed)39260412
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Albiñana, Carlos Berenguer $u IQVIA, London, United Kingdom
245    10
$a Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers / $c CB. Albiñana, M. Pallocca, H. Fenton, W. Sopwith, CV. Eden, O. Akre, A. Auranen, F. Bocquet, M. Borges, E. Calvo, J. Corkett, SD. Cosimo, N. Gentili, J. Guérin, S. Jor, T. Kazda, A. Kolar, T. Kuschel, MJ. Lostes, C. Paratore, P. Pedrazzoli, M. Petrovic, J. Raid, M. Roche, C. Schatz, J. Thonnard, G. Tonon, A. Traverso, A. Wolf, AH. Zedan, P. Mahon
520    9_
$a BACKGROUND: Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking. OBJECTIVES: The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development. METHODS: PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records. RESULTS: During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature. CONCLUSION: PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.
650    _2
$a lidé $7 D006801
650    _2
$a průzkumy a dotazníky $7 D011795
650    12
$a onkologická péče - zařízení $7 D002173
650    _2
$a nádory $7 D009369
650    _2
$a biomedicínský výzkum $7 D035843
650    _2
$a benchmarking $7 D019985
650    _2
$a lékařská onkologie $x metody $7 D008495
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pallocca, Matteo $u IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy
700    1_
$a Fenton, Hayley $u IQVIA, London, United Kingdom $u Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
700    1_
$a Sopwith, Will $u IQVIA, London, United Kingdom $u Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
700    1_
$a Eden, Charlie Van $u IQVIA, London, United Kingdom
700    1_
$a Akre, Olof $u Karolinska Comprehensive Cancer Center, Stockholm, Sweden
700    1_
$a Auranen, Annika $u Tays Cancer Centre, Pirkanmaa, Finland
700    1_
$a Bocquet, François $u Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France
700    1_
$a Borges, Marina $u IQVIA, London, United Kingdom $u Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal
700    1_
$a Calvo, Emiliano $u START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
700    1_
$a Corkett, John $u Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
700    1_
$a Cosimo, Serena Di $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Gentili, Nicola $u IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
700    1_
$a Guérin, Julien $u Data Office, Institut Curie, Paris, France
700    1_
$a Jor, Sissel $u Oslo University Hospital Cancer Center, Oslo, Norway
700    1_
$a Kazda, Tomas $u Masaryk Memorial Cancer Institute, Brno, Jihomoravský, Czechia
700    1_
$a Kolar, Alenka $u Institute of Oncology Ljubljana, Ljubljana, Slovenia
700    1_
$a Kuschel, Tim $u Charité, Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Lostes, Maria Julia $u Vall d'Hebron University Hospital, Barcelona, Spain
700    1_
$a Paratore, Chiara $u University Hospital San Luigi Gonzaga of Orbassano, Orbassano TO, Italy
700    1_
$a Pedrazzoli, Paolo $u Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia PV, Italy
700    1_
$a Petrovic, Marko $u Sestre Milosrdnice University Hospital, Zagreb, Croatia
700    1_
$a Raid, Jarno $u Tartu University Hospital, Tartu, Tartumaa, Estonia
700    1_
$a Roche, Miriam $u Trinity St James's Cancer Institute, Dublin, Ireland
700    1_
$a Schatz, Christoph $u Biobank Innsbruck, Innsbruck, Austria
700    1_
$a Thonnard, Joelle $u Cliniques Universitaires Saint-Luc, Brussels, Belgium
700    1_
$a Tonon, Giovanni $u IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Traverso, Alberto $u IRCCS San Raffaele Scientific Institute, Milan, Italy $u Maastricht Comprehensive Cancer Center, Maastricht, The Netherlands $u DIGICORE, Bruxelles, Belgium
700    1_
$a Wolf, Andrea $u University Cancer Center Frankfurt (UCT), University Hospital, Goethe University, Frankfurt, Germany
700    1_
$a Zedan, Ahmed H $u Vejle Hospital, University of Southern Denmark, Vejle, Denmark
700    1_
$a Mahon, Piers $u IQVIA, London, United Kingdom $u DIGICORE, Bruxelles, Belgium
773    0_
$w MED00188150 $t Applied clinical informatics $x 1869-0327 $g Roč. 15, č. 4 (2024), s. 743-750
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39260412 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110739 $b ABA008
999    __
$a ok $b bmc $g 2201946 $s 1231389
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c 4 $d 743-750 $e 20240911 $i 1869-0327 $m Applied clinical informatics $n Appl Clin Inform $x MED00188150
LZP    __
$a Pubmed-20241015
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace